Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Worth Seeing!
Invest in Cases Systematically - Every stock is handpicked
Start Buying Now
Start Buying Now
Gland Pharma is currently trading at Rs. 1709.90, up by 3.30 points or 0.19% from its previous closing of Rs. 1706.60 on the BSE.
The scrip opened at Rs. 1695.05 and has touched a high and low of Rs. 1723.25 and Rs. 1690.00 respectively. So far 2208 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2195.75 on 07-Feb-2024 and a 52 week low of Rs. 861.50 on 22-May-2023.
Last one week high and low of the scrip stood at Rs. 1763.00 and Rs. 1663.10 respectively. The current market cap of the company is Rs. 28084.79 crore.
The promoters holding in the company stood at 57.86%, while Institutions and Non-Institutions held 28.82% and 13.32% respectively.
Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for Edaravone Injection, 30 mg/100 mL (0.3 mg/mL) and 60 mg/100 mL (0.6 mg/mL), Single-Dose Bags. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Radicava Injection, 30 mg/100 mL (0.3 mg/mL) and 60 mg/100 mL (0.6 mg/mL) of Mitsubishi Tanabe Pharma Corporation.
The Product is used to treat amyotrophic lateral sclerosis (ALS), a condition in which the nerves that control muscle movement slowly die, causing the muscles to shrink and weaken. The Company expects to launch this Product through its marketing partner within FY25. According to IQVIA, the product had US sales of approximately $19 million for the twelve months ending January 2024.
Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1532.85 |
| Dr. Reddys Lab | 5812.50 |
| Cipla | 1403.90 |
| Zydus Lifesciences | 1104.45 |
| Lupin | 1661.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
